Maxalt

Rizatriptan, the active ingredient in Maxalt, is a Triptan presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks with or without aura in adult patients. GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxalt belongs to the triptan class and is used to treat acute migraine episodes. - Migraine with aura: provides rapid relief of headache and associated symptoms. - Migraine without aura: reduces pain intensity and duration of the attack. - Acute migraine attacks in adults: offers a targeted therapeutic option for prompt symptom control.

Adverse reactions may occur with any medication.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Dizziness or light‑headedness - Nausea or abdominal pain - Fatigue or drowsiness - Dry mouth

Serious or Rare Side Effects: - Coronary vasospasm or myocardial infarction - Serotonin syndrome, especially with other serotonergic agents - Severe allergic reactions such as anaphylaxis - Persistent or worsening headache - Severe hypertension or arrhythmia

Before using Maxalt, consider the following safety points. - Cardiovascular disease: avoid use in patients with uncontrolled heart conditions. - History of stroke or transient ischemic attack: contraindicated. - Concomitant use of MAO inhibitors: not recommended within 14 days. - Pregnancy: risk category unknown; discuss with a healthcare professional. - Serotonergic medication: assess risk of serotonin syndrome. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Rizatriptan may interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension and serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Ergot alkaloids: additive vasoconstrictive effects. - Other triptans: cumulative triptan exposure may raise cardiovascular risk. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase rizatriptan plasma levels. - Antihypertensive agents: monitor blood pressure for additive effects.